Categories
Change Password!
Reset Password!
This pilot clinical trial aimed to evaluate whether a single injectable platelet-rich fibrin (I-PRF) injection into the temporomandibular joint (TMJ) effectively alleviates joint-related pain.
A single intra-articular injection of injectable platelet-rich fibrin substantially reduces both spontaneous and provoked temporomandibular joint articular pain within 14 days.
This pilot clinical trial aimed to evaluate whether a single injectable platelet-rich fibrin (I-PRF) injection into the temporomandibular joint (TMJ) effectively alleviates joint-related pain.
The study enrolled adult patients with a prior history of TMJ articular pain management. Each volunteer received one I-PRF injection into the symptomatic TMJ. Assessments were conducted before and 14 days post-treatment and included: (1) self-reported TMJ pain over the past week, (2) pain elicited during physical examination, (3) muscular discomfort, (4) headache, and (5) neck pain. Additionally, the examiner recorded measurements of pain-free mandibular opening and maximum voluntary jaw opening.
A total of 33 patients (44 TMJs) were evaluated. No complications were noted at the injection sites. The treatment led to a prominent reduction in both spontaneous and provoked articular pain, as assessed on the visual analog scale (VAS; Table 1):
Among patients classified as Wilkes stage II–V, 39–48% showed improvement, while 5–14% reported a worsening of up to 2 VAS points. Mandibular opening range dropped slightly by 1–2 mm, and no vital changes were noted in muscle pain, headaches, or neck discomfort.
A single I-PRF injection into the TMJ offers statistically significant relief from joint pain. For individuals who do not respond to the initial therapy, repeated injections may be considered.
Dental and Medical Problems
Single intra-articular administration of injectable platelet-rich fibrin (I-PRF) in alleviating temporomandibular joint pain: A pilot clinical trial
Marcin Sielski et al.
Comments (0)